Georgia Medicare Part D Out-of-Pocket Cap Guide 2026

By Brevy Care Team

What is the Medicare Part D Out-of-Pocket Cap?

The Medicare Part D Out-of-Pocket Cap is the annual maximum amount that a Medicare Part D enrollee can be required to pay out-of-pocket for covered prescription drugs in a calendar year. It was established by Section 11201 of the Inflation Reduction Act of 2022 (Public Law 117-169, signed by President Joe Biden on August 16, 2022) and codified at Section 1860D-2(b)(4) of the Social Security Act.

Before the IRA, Medicare Part D had no annual out-of-pocket maximum. The Part D benefit structure included a deductible phase, an initial coverage phase, a coverage gap (the so-called "donut hole"), and a catastrophic phase. In the catastrophic phase, beneficiaries still paid 5% coinsurance, which for high-cost specialty drugs meant continuing to pay hundreds or thousands of dollars per fill, with no annual ceiling. Seniors taking expensive oncology drugs, autoimmune biologics, multiple sclerosis therapies, hepatitis C antivirals, or other specialty medications routinely faced annual out-of-pocket spending of thousands of dollars, with no ceiling.

The IRA closed this gap in phases:

• January 1, 2024: The 5% beneficiary coinsurance in the catastrophic phase was eliminated. This substantially reduced out-of-pocket exposure for beneficiaries who previously entered the catastrophic phase.
• January 1, 2025: A hard $2,000 annual out-of-pocket cap took effect.
• January 1, 2026: The cap rose to $2,100 (CPI-U adjusted upward).
• Subsequent years: Continued annual CPI-U adjustment.

The OOP cap is one piece of a broader, IRA-driven Part D redesign that also includes:

1. Medicare Drug Price Negotiation Program — Maximum Fair Prices (MFPs) for an initial set of Part D drugs effective January 1, 2026 (additional cycles to follow).
2. Manufacturer Discount Program — Replaced the Coverage Gap Discount Program effective January 1, 2025; manufacturers contribute 10% in the initial coverage phase and 20% in the catastrophic phase.
3. Insulin copay cap — Effective January 1, 2023 for Part D insulin; July 1, 2023 for Part B insulin pumps.
4. Expanded Low-Income Subsidy / Extra Help — IRA Section 11404 expanded full LIS eligibility to beneficiaries at a higher income level effective January 1, 2024.
5. Medicare Prescription Payment Plan (M3P) — Effective January 1, 2025, allows Part D enrollees to smooth their out-of-pocket costs over the calendar year in monthly installments rather than paying large amounts at any single fill.
6. Elimination of the Coverage Gap — The "donut hole" coverage gap was effectively eliminated by the 2025 redesign, replaced by a streamlined deductible / initial coverage / catastrophic structure.

For Georgia seniors, the OOP cap and the broader Part D redesign represent the most significant senior-friendly drug benefit reform since Part D was created by the Medicare Modernization Act of 2003.

Why the Part D Out-of-Pocket Cap matters for Georgia eldercare

For Georgia seniors and their families, the OOP cap directly transforms the financial calculus of prescription drug coverage. Hundreds of thousands of Georgia Medicare beneficiaries take medications that, under pre-IRA Part D, would have generated thousands of dollars in annual out-of-pocket spending. Under the post-IRA design, that spending is now capped at $2,100 per year (2026).

Specifically for Georgia:

• Georgia Medicare beneficiaries enrolled in Part D or MA-PD plans are protected by the OOP cap.
• Tens of thousands of Georgia seniors with cancer, autoimmune disease, multiple sclerosis, hepatitis C, or other high-cost conditions previously hit catastrophic-phase spending each year. Now their total annual OOP is capped.
• Dual-eligibles with full Extra Help / LIS already pay very low fixed copays ($0 generic / $4-$10 brand depending on category), so the OOP cap is less impactful for them — but they still benefit from the broader redesign.
• Partial LIS beneficiaries (expanded income threshold post-IRA) now receive expanded Extra Help and are protected by the cap.
• Non-LIS beneficiaries receive the most direct financial protection — for the first time, their Part D OOP spending has a hard ceiling.
• The cap interacts with the Medicare Drug Price Negotiation Program's MFPs (effective January 1, 2026 for first-cycle drugs) to compound savings: MFP reduces the price per fill; the cap limits total annual spending.
• The Manufacturer Discount Program's 10%/20% manufacturer contributions also contribute to lower beneficiary spending in the initial coverage and catastrophic phases.
• Georgia Part D / MA-PD plan sponsors — Humana, UnitedHealthcare, Aetna (CVS Health), Anthem (Elevance), Wellcare (Centene), Cigna, and others — must adjudicate the cap in real time at the pharmacy.
• The Medicare Prescription Payment Plan (M3P) allows beneficiaries to smooth costs over the year — particularly valuable for seniors who hit their cap early in the year on a single specialty drug.

The economics matter especially for senior beneficiaries because:

1. The cap eliminates "catastrophic financial harm" risk that previously affected seniors on specialty drugs.
2. The cap interacts with negotiated MFPs to make some previously-unaffordable medications affordable.
3. The cap pairs with the M3P to spread payments evenly across the year for predictable budgeting.
4. The cap reduces medication non-adherence driven by cost (a major cause of avoidable hospitalizations among seniors).
5. The cap reduces caregiver financial burden for families supporting seniors with high drug costs.

Statutory and regulatory foundation

Section 11201 of the Inflation Reduction Act of 2022

Section 11201 of the IRA (Public Law 117-169, August 16, 2022) amended Section 1860D-2 of the Social Security Act to establish the annual out-of-pocket threshold and phase in the cap. Key provisions:

• Elimination of the 5% catastrophic-phase coinsurance effective January 1, 2024.
• $2,000 annual OOP cap effective January 1, 2025.
• Annual CPI-U adjustment for 2026 and subsequent years.
• Coordination with the new Manufacturer Discount Program (Section 11202).

Section 1860D-2(b)(4) of the Social Security Act

The codified statute establishing the annual out-of-pocket threshold for Part D. It defines:

• The threshold amounts (with annual CPI-U adjustments).
• The methodology for determining "incurred costs" counted toward the threshold (the so-called "True Out-of-Pocket" or TrOOP calculation).
• The relationship between manufacturer discounts, plan payments, and beneficiary OOP for purposes of the cap.
• Coordination with other federal and state programs.

CMS implementing guidance

CMS published implementing guidance:

• CMS Final Part D Redesign Program Instructions (April 2024) — initial implementation for plan year 2025.
• CMS Final Part D Redesign Program Instructions for Plan Year 2026 (April 2025) — refined guidance for 2026 including the $2,100 amount.
• CMS Medicare Prescription Payment Plan Guidance (June 2024 — final) — M3P operational rules.
• CMS Insulin Cost-Sharing Cap Implementation Guidance — multiple memoranda.
• Annual Final Rate Notice and Call Letter — guidance for plan year operations.

The Part D benefit structure post-IRA (effective January 1, 2025)

Pre-IRA Part D had four phases: deductible, initial coverage, coverage gap (donut hole), and catastrophic. The 2025 redesign collapsed this into three phases:

1. Deductible phase

Beneficiary pays 100% of drug costs up to the standard Part D annual deductible set by CMS each year. Some Part D plans have lower deductibles (down to $0 for certain plan designs); LIS beneficiaries have $0 deductible.

2. Initial coverage phase

After meeting the deductible (or from $1 for $0-deductible plans), beneficiary pays a standard coinsurance share for covered drugs. Manufacturers pay 10% via the Manufacturer Discount Program for applicable brand drugs.

This phase continues until the beneficiary's TrOOP spending reaches the OOP cap.

3. Catastrophic phase

After the OOP cap is reached, beneficiary pays $0 for covered Part D drugs for the remainder of the calendar year. Manufacturers contribute 20% of the remaining drug cost via the Manufacturer Discount Program; the plan and federal reinsurance split the remainder under CMS rules.

The catastrophic phase was previously a 5% beneficiary coinsurance phase (pre-2024) and a high-threshold phase (2024 only); from 2025 onward, it's the $2,000 cap / $2,100 (2026) cap.

How the OOP cap is calculated

The OOP cap counts True Out-of-Pocket (TrOOP) costs, defined under Section 1860D-2(b)(4)(C). TrOOP includes:

• Beneficiary deductible payments.
• Beneficiary coinsurance and copayments.
• Manufacturer Discount Program manufacturer contributions on brand drugs (counted toward beneficiary TrOOP for cap purposes, a critical design feature that allows beneficiaries to reach the cap faster).
• Certain qualifying payments by third parties (LIS, State Pharmaceutical Assistance Programs, certain charitable programs).

TrOOP does NOT include:

• Part D premiums.
• Part D plan payments.
• Federal reinsurance payments.
• Manufacturer Coverage Gap Discount Program payments (the program was replaced effective 2025).
• Non-covered drug costs (drugs not on the formulary).

The TrOOP calculation accelerates reaching the cap, particularly for beneficiaries taking brand drugs subject to the Manufacturer Discount Program.

Medicare Prescription Payment Plan (M3P) — monthly smoothing

The Medicare Prescription Payment Plan (M3P), established by Section 11202 of the IRA, became effective January 1, 2025. M3P allows Part D enrollees to smooth their out-of-pocket costs over the calendar year in equal monthly installments rather than paying large amounts at any single fill.

How M3P works:

1. The beneficiary opts in to M3P at the start of the plan year or any time during the year.
2. At the pharmacy, the beneficiary pays $0 out-of-pocket for the dispensed drug (the plan pays the pharmacy directly).
3. The plan calculates the beneficiary's total estimated annual OOP and bills the beneficiary in equal monthly installments for the remainder of the calendar year.
4. The monthly bill is separate from the Part D premium.

M3P is particularly valuable for beneficiaries who hit their OOP cap early in the year on a single specialty drug. Without M3P, a beneficiary who hits the full cap on a specialty drug in January pays the entire cap amount immediately, then $0 for the rest of the year. With M3P, that beneficiary pays equal monthly installments spread across the year.

M3P does NOT reduce the total amount owed — it spreads the payment. Beneficiaries who do not pay their monthly M3P bill may have plan-imposed consequences (loss of M3P eligibility for the year, collection on the unpaid amount).

Manufacturer Discount Program (replacing Coverage Gap Discount Program)

Section 11202 of the IRA created the Manufacturer Discount Program for Part D effective January 1, 2025, replacing the Coverage Gap Discount Program (CGDP) that existed from 2011 to 2024.

How it works:

• For applicable brand drugs (drugs from manufacturers participating in the Discount Program), manufacturers pay a percentage of the drug cost:
  • 10% in the initial coverage phase (post-deductible, pre-cap).
  • 20% in the catastrophic phase (post-cap).
• Manufacturers can elect to participate or face exclusion of their drugs from Part D coverage (similar leverage to MDRP).
• Practically, all manufacturers participate.

The Manufacturer Discount Program affects:

• Beneficiary TrOOP: Manufacturer discounts in the initial coverage phase count toward the beneficiary's TrOOP, accelerating reaching the OOP cap.
• Plan costs: Plans benefit from manufacturer discounts in both phases.
• Federal reinsurance: The federal government's reinsurance obligation in the catastrophic phase is reduced.

Insulin copay cap

Section 11406 of the IRA established the insulin copay cap for Medicare Part D effective January 1, 2023. The cap:

• Limits beneficiary cost-sharing to a statutory maximum per 30-day supply for any Part D-covered insulin product.
• Applies to all Part D and MA-PD plans.
• Was extended to Part B insulin pumps effective July 1, 2023.
• Pairs with the Drug Price Negotiation Program for certain insulin products where the MFP also applies effective January 1, 2026.

For Georgia diabetes patients, the insulin copay cap is independent of the broader OOP cap — the insulin copay cap applies even before the beneficiary's deductible is met.

Expanded LIS / Extra Help (effective January 1, 2024)

Section 11404 of the IRA expanded full Low-Income Subsidy (Extra Help) eligibility:

• Pre-IRA: Full LIS available to beneficiaries up to a lower income threshold.
• Post-IRA (effective January 1, 2024): Full LIS available to beneficiaries up to a higher income threshold.

The expansion brought hundreds of thousands of additional Medicare beneficiaries nationally into full LIS protection. For Georgia, this expansion benefited senior beneficiaries with modest incomes who previously had only partial LIS.

Full LIS provides:

• $0 Part D premium (up to the regional benchmark).
• $0 Part D deductible.
• Low fixed copays for generics and brand drugs; $0 in long-term care.
• $0 OOP after passing the catastrophic threshold.

Best practices for Georgia stakeholders

1. Beneficiaries: enroll in M3P if you expect high drug costs. Smooth your costs across the year rather than paying a large amount on one fill.

2. Beneficiaries: confirm your formulary covers your drugs each year. Plans may change formularies between years; what's covered in 2025 may not be in 2026.

3. Beneficiaries: use GeorgiaCares SHIP for plan comparisons. Annual Enrollment Period is October 15 - December 7 each year; SHIP counselors compare plans for your specific drug list.

4. Beneficiaries: apply for Extra Help / LIS if you have modest income. Post-IRA expanded eligibility may include many beneficiaries who didn't qualify before.

5. Beneficiaries: track your TrOOP spending. Plans show TrOOP on Explanation of Benefits; once you hit the cap, you owe $0 for covered drugs the rest of the year.

6. Beneficiaries: use the insulin copay cap. Even before your deductible, your insulin cost-sharing is capped by federal law.

7. Prescribers: prescribe with awareness of the cap. Patients are more likely to be adherent now that catastrophic financial harm is bounded.

8. Prescribers: use specialty pharmacy networks correctly. Specialty drugs (oncology, MS, autoimmune) typically go through specialty pharmacy networks; coordinate with the plan.

9. Pharmacies: adjudicate the cap accurately at point of sale. Plans report TrOOP; pharmacies should display the cap status to beneficiaries on receipt.

10. Pharmacies: offer M3P education at point of sale. When a beneficiary faces a large fill cost, pharmacists can suggest M3P enrollment.

11. Plans: report TrOOP and cap status accurately. Member-facing communications should clearly show cap progress.

12. Plans: process M3P enrollment and billing accurately. M3P is a new program; operational accuracy is critical.

13. Caregivers: help seniors track drug spending and benefits. Caregiver awareness of M3P, LIS, and the OOP cap helps optimize coverage.

14. Healthcare systems: incorporate Part D redesign into care management. Care managers should know whether patients have hit cap, are in M3P, and have LIS — to manage clinical and financial barriers to adherence.

Common issues and how to avoid them

1. Beneficiaries not knowing the cap exists. Many seniors are unaware of the IRA OOP cap. Prevention: SHIP outreach, plan member education.

2. M3P enrollment confusion. Beneficiaries may not understand M3P or how to enroll. Prevention: plan and pharmacy point-of-sale education.

3. M3P non-payment. Beneficiaries who don't pay their monthly M3P bill may lose M3P eligibility for the year. Prevention: budget for M3P installments.

4. TrOOP tracking errors. Plans may miscalculate TrOOP if claims data is incomplete. Prevention: beneficiaries verify TrOOP on EOB.

5. Specialty drug formulary placement. Plans may place specialty drugs in unfavorable tiers. Prevention: compare plans during AEP based on your specific drug list.

6. Prior authorization barriers. Even with the cap, PA can delay specialty drug access. Prevention: prescribers complete PA promptly and thoroughly.

7. Plan formulary changes year-over-year. Drugs covered in 2025 may be excluded or higher-tier in 2026. Prevention: review the Annual Notice of Change (ANOC) each fall.

8. Coordination with Medicaid / dual-eligible. Dual-eligibles with Medicaid wrap may experience coordination errors. Prevention: confirm dual-eligible status with both Medicare and Georgia Medicaid.

9. MA-PD plan benefit design. MA-PD plans may have unique benefit structures. Prevention: read the Evidence of Coverage carefully.

10. Insulin cap miscalculation. The insulin copay cap applies per insulin product per 30-day supply; some beneficiaries take multiple insulins. Prevention: verify pharmacy bills.

11. Manufacturer discount program adjudication errors. Plans/pharmacies may miscalculate manufacturer contributions. Prevention: pharmacy QA processes.

12. LIS qualification uncertainty. Beneficiaries may not know they qualify under expanded LIS. Prevention: apply through Social Security or Georgia DCH.

13. Charitable assistance program coordination. Some patient assistance programs interact with TrOOP calculations in complex ways. Prevention: confirm program rules with the assistance provider.

14. Catastrophic phase 2024 transition confusion. Beneficiaries who hit catastrophic in 2024 may have expected continued spending; 2024 was the transition year. Prevention: plan communications about phase changes.

Worked examples

Example 1: Fulton County — 70-year-old Atlanta cancer patient hitting $2,100 cap quickly

Ms. Williams is 70, lives in Atlanta, and was diagnosed with metastatic breast cancer in 2025. Her oncologist at Emory Winship Cancer Institute prescribed a Part D-covered oral oncology agent that costs approximately $14,000 per 30-day supply.

In January 2026, Ms. Williams fills her first prescription. Her Part D plan adjudicates the claim:

• She first pays the standard Part D annual deductible.
• Initial coverage phase: she pays a standard coinsurance share on the remaining drug cost until she reaches the $2,100 out-of-pocket cap.
• Given the high drug price, Ms. Williams reaches the $2,100 cap within her first fill.
• For the rest of 2026, Ms. Williams pays $0 for her oral oncology drug.

Ms. Williams also enrolled in M3P, so instead of paying the full cap amount upfront in January, she pays equal monthly installments spread across the year. This makes her drug spending predictable and budgetable.

Without the IRA OOP cap, Ms. Williams's annual out-of-pocket spending on a drug of this price would have been substantially higher — with no ceiling under the old Part D structure.

Example 2: DeKalb County — 75-year-old DeKalb dual-eligible — no impact from OOP cap

Mrs. Johnson is 75, dual-eligible for Medicare and Georgia Medicaid, and has full Extra Help / LIS. She takes 6 medications for hypertension, diabetes, hyperlipidemia, GERD, depression, and osteoporosis.

Because of her full LIS status, Mrs. Johnson's cost-sharing is already capped at low fixed copays ($0 for generics; low fixed copays for brand drugs; $0 in long-term care). Her total annual OOP is typically well below the $2,100 cap.

For Mrs. Johnson, the OOP cap is not the most important IRA reform — her LIS protections already provide robust affordability. However, the broader Part D redesign, the Manufacturer Discount Program, and (when applicable) the Medicare Drug Price Negotiation Program MFPs benefit the federal Medicare program and her Part D plan, which over time supports lower premiums and more plan options.

Example 3: Cobb County — 68-year-old Cobb MS patient on specialty drug — full cap impact

Mrs. Rodriguez is 68 and lives in Cobb County. She has relapsing-remitting multiple sclerosis and takes a Part D-covered oral disease-modifying therapy that costs approximately $7,800 per 30-day supply. Her neurologist at WellStar MS Center manages her care.

In January 2026, Mrs. Rodriguez fills her DMT:

• She pays the standard Part D annual deductible.
• She pays a standard coinsurance share on the remaining amount until reaching the $2,100 cap.
• After her first January fill, Mrs. Rodriguez has reached the cap.
• For February through December 2026, Mrs. Rodriguez pays $0 for her DMT.

She enrolls in M3P, spreading her $2,100 cap across equal monthly installments throughout the year. Combined with the cap and M3P, her 2026 drug budget is predictable and stable.

Without the OOP cap, Mrs. Rodriguez's pre-IRA out-of-pocket spending on a drug of this price would have been substantially higher — potentially several thousand dollars annually.

Example 4: Worth County — 72-year-old rural Worth County COPD + 8 medications — partial cap

Mr. Davis is 72 and lives in Worth County in rural southwest Georgia. He has COPD, heart failure, diabetes, hypertension, and depression. He takes 8 medications — a mix of generics, brand-name combination inhalers, and one specialty biologic for severe asthma (Nucala/mepolizumab).

His total annual drug spending without IRA reforms would be approximately $4,000-$5,000 OOP. With the IRA reforms:

• Generic drug copays remain low ($1-$5 per fill).
• Brand drug coinsurance applies post-deductible in the initial coverage phase.
• His biologic Nucala contributes substantially toward TrOOP — he hits the $2,100 cap by approximately May 2026.
• From June 2026 onward, Mr. Davis pays $0 for covered drugs.

With M3P, Mr. Davis spreads his anticipated $2,100 cap across equal monthly installments throughout the year.

Mr. Davis is not currently LIS-eligible (his Social Security and small pension push his income above the LIS threshold by a modest margin), so the cap is the primary protection for him. SHIP counselors at GeorgiaCares confirmed his Extra Help non-eligibility but emphasized the cap and M3P benefits.

Example 5: Bibb County — 80-year-old Bibb autoimmune patient on Stelara + cap + MFP combined

Mrs. Thompson is 80 and lives in Macon. She has severe psoriatic arthritis and takes Stelara (ustekinumab) — administered every 8 weeks. Stelara is one of the first-cycle Medicare Drug Price Negotiation Program drugs, with a significantly reduced Maximum Fair Price effective January 1, 2026.

Mrs. Thompson's first Stelara dose in early 2026:

• She pays the standard Part D annual deductible.
• She pays a standard coinsurance share on the remaining amount until she reaches the $2,100 cap.
• After her first Stelara dose, Mrs. Thompson reaches the $2,100 cap.
• For the rest of 2026, Mrs. Thompson pays $0 for all her Part D drugs.

The combination of the reduced MFP (cutting the per-dose price substantially from the prior list price) and the OOP cap ($2,100 maximum) is transformative for patients on high-cost biologics.

Mrs. Thompson enrolled in M3P for predictable monthly budgeting.

Example 6: Hall County — 67-year-old Hall County CLL patient Imbruvica + cap + MFP combined

Mr. Patel is 67, lives in Gainesville, and has chronic lymphocytic leukemia (CLL). His oncologist at Northeast Georgia Medical Center prescribed Imbruvica (ibrutinib) — a daily oral targeted therapy and a first-cycle Drug Price Negotiation Program drug with a significantly reduced Maximum Fair Price effective January 1, 2026.

In January 2026:

• Mr. Patel pays the standard Part D annual deductible.
• He pays a standard coinsurance share until reaching the $2,100 cap.
• After his January fill, Mr. Patel has reached the cap.
• For February through December 2026, Mr. Patel pays $0.

M3P spreads his cap payment across equal monthly installments throughout the year.

The reduced MFP, the OOP cap, and M3P together make Imbruvica financially sustainable for the long-term CLL treatment Mr. Patel needs.

Frequently Asked Questions

Call to action — Georgia Medicare Part D resources

If you, a family member, or someone you care for is enrolled in Medicare Part D or an MA-PD plan, the contacts below can help with cap questions, M3P enrollment, plan comparisons, and Extra Help applications.

• Medicare: 1-800-MEDICARE (1-800-633-4227)
• CMS Part D Redesign: cms.gov/inflation-reduction-act-and-medicare/part-d-redesign-program-instructions
• GeorgiaCares (Georgia SHIP): 1-866-552-4464 — free Part D plan counseling
• Medicare Rights Center: 1-800-333-4114
• Patient Advocate Foundation: 1-800-532-5274
• NeedyMeds: 1-800-503-6897
• Georgia DCH Member Services: 1-866-211-0950
• Magellan Medicaid Administration Georgia: 1-800-424-9760
• Atlanta Legal Aid: 404-377-0701
• Georgia Legal Services Program: 1-800-498-9469
• Eldercare Locator: 1-800-677-1116
• 211 Georgia: dial 211
• Social Security Administration (Extra Help applications): 1-800-772-1213
• Humana Member Services: 1-800-457-4708
• UnitedHealthcare Medicare: 1-800-721-0627
• Aetna Medicare: 1-800-282-5366
• American Cancer Society: 1-800-227-2345
• Multiple Sclerosis Association of America: 1-800-532-7667

Find personalized help navigating Medicare Part D in Georgia at brevy.com.